Taurolidine Synthesis and Polymorph Purity for Catheter Locks
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing taurolidine synthesis methods result in high levels of impurities and residual solvents, which can lead to catheter-related infections and coagulation issues, and conventional catheter lock solutions lack biocidal capability.
Innovation Solution
A novel synthesis method using Pearlman's catalyst and Hydrochloric acid, along with Class 3 solvents like acetone, reduces impurities and produces taurolidine polymorphs (Polymorph A and B) with improved purity and lower toxicity, enhancing the biocidal properties of taurolidine-based catheter lock solutions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional synthesis methods are used to produce taurolidine, then the synthesis process is simple and cost-effective, but the product contains high levels of impurities and residual solvents
Solution Approach 1:
The synthesis process is divided into multiple discrete steps including catalytic hydrogenation, filtration, concentration, and crystallization. Each step targets specific impurities or solvents, allowing systematic purification without requiring complete process redesign.
Solution Approach 2:
Pearlman's catalyst (Pd(OH)2/CaCO3) is introduced as an intermediary substance to facilitate selective hydrogenation reactions. The catalyst enables specific chemical transformations that remove impurities while being easily separable from the final product through filtration.
2Reliability
If conventional catheter lock solutions are used, then the solutions provide anticoagulant activity, but they lack biocidal capability and can promote bacterial growth
Solution Approach 1:
The patent combines taurolidine (providing biocidal activity) with heparin or LMWH (providing anticoagulant activity) in a single catheter lock solution formulation. This merging of functions ensures both antimicrobial protection and prevention of catheter occlusion by clots.
Solution Approach 2:
The catheter lock solution is formulated as a composite system containing multiple active ingredients (taurolidine and heparin/LMWH) with complementary mechanisms of action. The composite formulation addresses multiple clinical requirements simultaneously that cannot be met by single-agent solutions.
3Reliability
If antibiotics are used prophylactically in catheter lock solutions, then infection prevention is enhanced, but antibiotic-resistant bacterial strains emerge
Solution Approach 1:
The patent employs taurolidine, a non-antibiotic biocide that does not select for resistant strains through repeated exposure. Unlike antibiotics, taurolidine maintains effective antimicrobial activity without promoting resistance, making it suitable for repeated prophylactic use in catheter lock solutions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The improved synthesis method results in taurolidine with reduced impurities and residual solvents, providing enhanced biocidal and anticoagulant efficacy, thereby reducing catheter-related infections and coagulation complications.
Implementation Method 1
The method may comprise the following steps: a) hydrogenating Cbz-taurinamide with Pearlman's catalyst to form a reaction mixture
Implementation Method 2
a) hydrogenating Cbz-taurinamide with Pearlman's catalyst to form a reaction mixture
Implementation Method 3
b) concentrating the reaction mixture to provide taurolidine
Implementation Method 4
The taurolidine may be a polymorph, for example, Polymorph A as demonstrated by an X-ray powder diffraction (XRPD) in FIG. 2 and/or Polymorph B as demonstrated by an XRPD in FIG. 3
Data Source
AI summary
Improved methods for synthesizing taurolidine, improved compositions or formulations comprising taurolidine and methods for reducing an amount of impurities in taurolidine are provided herein, among other things. The taurolidine may be substantially free of impurities. The taurolidine may be a polymorph, for example, Polymorph A as characterized by the XRPD in FIG. 2 and/or Polymorph B as characterized by the XRPD in FIG. 3.